{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:09:43Z","timestamp":1792498183215,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.schres.2018.05.028","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T20:12:37Z","timestamp":1527192757000},"page":"324-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study"],"prefix":"10.1016","volume":"201","author":[{"given":"Rama","family":"Melkote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Remmerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Savitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.schres.2018.05.028_bb0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5498\/wjp.v2.i5.74","article-title":"Medication adherence in schizophrenia","volume":"2","author":"Acosta","year":"2012","journal-title":"World J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2018.05.028_bb0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.psychres.2004.11.002","article-title":"A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia","volume":"133","author":"Byerly","year":"2005","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.schres.2018.05.028_bb0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.psc.2007.04.002","article-title":"Antipsychotic medication adherence in schizophrenia","volume":"30","author":"Byerly","year":"2007","journal-title":"Psychiatr. Clin. North. Am."},{"issue":"1","key":"10.1016\/j.schres.2018.05.028_bb0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.schres.2018.05.028_bb0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/psp4.12212","article-title":"Optimizing antipsychotic patient management using population pharmacokinetic models and point-of-care testing","volume":"6","author":"Green","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"6","key":"10.1016\/j.schres.2018.05.028_bb0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"10.1016\/j.schres.2018.05.028_bb0035","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1176\/appi.ajp.2016.16040402","article-title":"The role of antipsychotic plasma levels in the treatment of schizophrenia","volume":"174","author":"Horvitz-Lennon","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2018.05.028_bb0040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2018.05.028_bb0045","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2018.05.028_bb0050","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/psp4.12217","article-title":"Determination of plasma concentration reference ranges for risperidone and Paliperidone","volume":"6","author":"Korell","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.schres.2018.05.028_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-018-2419-3","article-title":"Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine","author":"Korell","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.schres.2018.05.028_bb0060","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2018.05.028_bb0065","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.schres.2018.05.028_bb0070","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.12117tx2c","article-title":"Monitoring treatment and managing adherence in schizophrenia","volume":"74","author":"Marder","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2018.05.028_bb0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","article-title":"Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia","volume":"176","author":"Novick","year":"2010","journal-title":"Psychiatry Res."},{"issue":"10","key":"10.1016\/j.schres.2018.05.028_bb0080","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.4088\/JCP.v67n1008","article-title":"Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review","volume":"67","author":"Valenstein","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 4","key":"10.1016\/j.schres.2018.05.028_bb0085","first-page":"1","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2018.05.028_bb0090","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","article-title":"Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia","volume":"55","author":"Weiden","year":"2004","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2018.05.028_bb0095","unstructured":"World Health Organization, 2017. Mental Health, Schizophrenia. (http:\/\/www.who.int\/mental_health\/management\/schizophrenia\/en\/ (Accessed July 14, 2017))."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418302858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418302858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T19:37:18Z","timestamp":1565293038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996418302858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":19,"alternative-id":["S0920996418302858"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2018.05.028","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2018.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}